Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 101,000 shares, a growth of 288.5% from the October 15th total of 26,000 shares. Based on an average daily trading volume, of 423,900 shares, the days-to-cover ratio is presently 0.2 days. Currently, 7.4% of the shares of the stock are sold short.

Evoke Pharma Trading Down 7.1 %

Shares of Evoke Pharma stock traded down $0.38 during trading on Tuesday, reaching $5.00. The company’s stock had a trading volume of 73,934 shares, compared to its average volume of 128,880. The stock has a 50-day moving average price of $5.06 and a two-hundred day moving average price of $5.52. The stock has a market capitalization of $4.10 million, a P/E ratio of -0.49 and a beta of 0.36. Evoke Pharma has a one year low of $3.54 and a one year high of $17.88.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 514.74% and a negative net margin of 71.32%. The company had revenue of $2.55 million during the quarter.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Evoke Pharma in a research note on Tuesday. They issued a “sell” rating for the company.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.